Novartis Unit Sued by Oriel Shareholders Over Buyout

Novartis AG, Europe’s largest drugmaker by revenue, was sued by investors in Oriel Therapeutics over claims one of its units defrauded them as part of an acquisition of the U.S. maker of respiratory drugs.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.